Azure Health Technology Limited trading as VGI Health Technology (NSX:VTL) is pleased to announce that an additional current Good Manufacturing Practice (cGMP) manufacturer has been appointed in the US.
Anatara Lifesciences (ASX:ANR), a developer of evidence based solutions for gastrointestinal diseases in humans and animals is pleased to provide this update on clinical trial activities.
Anatara Lifesciences (ASX:ANR), a developer of non-antibiotic oral solutions for gastrointestinal diseases in animals and humans, is pleased to provide this activities report for the quarter ending 31 March 2021, along with the Company's Appendix 4C cash flow report.
Anatara Lifesciences (ASX:ANR) is pleased to advise that it is has received Human Research Ethics Committee (HREC) approval to undertake a clinical trial on the effects of 3FDC dietary supplementation on psychological functioning in an adult population.
Anatara Lifesciences Ltd (ASX:ANR) is pleased to announce the grant of patent number AU2019204496 entitled "Anti-diarrhea formulation which avoids antimicrobial resistance".
Anatara is pleased that activities for the March quarter progressed favourably and near to anticipated timelines. There appears to be a wider appreciation of Anatara's human health initiatives with a focus on using the restoration and/or maintenance of gastrointestinal tract harmony to improve overall wellbeing.
On 14 December 2020, Anatara Lifesciences Limited (ASX:ANR) announced details of an off-market share buy-back facility (Buy-Back Facility) to buyback all of the shares held by shareholders who held unmarketable parcels of shares in the Company.
